☰

Kenneth F. Blount, Ph.D. - Publications

Affiliations: 
2002 University of Colorado, Boulder, Boulder, CO, United States 
Area:
Biochemistry, General Biophysics, Molecular Biology
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Orenstein R, Su X, Gonzalez C, Shannon B, Blount K, Bancke L, Gerding DN. Mo1949 ONE AND DONE? EVALUATION OF EFFICACY FROM A SINGLE ADMINISTRATION OF INVESTIGATIONAL MICROBIOTA-BASED DRUG RBX2660 FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: COMPARISON TO SINGLE-ADMINISTRATION FECAL MICROBIOTA TRANSPLANT IN PUBLISHED TRIALS Gastroenterology. 158: S-989-S-990. DOI: 10.1016/S0016-5085(20)33146-2  0.335
2020 Ray A, Harvey AJ, Gonzalez C, Shannon B, Bancke L, Blount K. Mo1930 THE DONOR DOES NOT MATTER IN THE FIGHT AGAINST RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: RESULTS FROM TWO CLINICAL TRIALS EVALUATING THE SAFETY AND EFFICACY OF INVESTIGATIONAL MICROBIOTA-BASED DRUG RBX2660 Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)33127-9  0.331
2019 Blount KF, Shannon WD, Deych E, Jones C. Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic. Open Forum Infectious Diseases. 6: ofz095. PMID 31024971 DOI: 10.1093/Ofid/Ofz095  0.314
2019 Ray A, Mische S, Blount K, Bancke L, Su X, Harvey A, Gerding D. 2822 Twelve-Month Durability of Microbiota-Based Drug RBX2660 for Preventing Clostridioides difficile Infection (CDI) Is Not Associated With Patient Demographics: Sub-Population Analysis of a Phase 2 Open-Label Study The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000600820.07183.Be  0.315
2019 Orenstein R, Mische S, Blount K, Bancke L, Su X, Walsh D, Harvey A, Gonzalez C, Gerding DN. LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections Open Forum Infectious Diseases. 6. DOI: 10.1093/Ofid/Ofz415.2488  0.346
2019 Hau H, Mische S, Klein S, Blount K. 670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660 Open Forum Infectious Diseases. 6. DOI: 10.1093/Ofid/Ofz360.738  0.351
2019 Jones C, Mische S, Blount K, Shannon B. 669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection Open Forum Infectious Diseases. 6. DOI: 10.1093/Ofid/Ofz360.737  0.311
2019 Khanna S, Pardi DS, Gerding DN, Blount K, Jones CR, Shannon B, Deych E. Tu1880 – Durable Freedom from Clostridium Difficile Infection Recurrence and Microbiome Restoration During Six-Month Follow-Up For a Phase 1 Clinical Trial of Rbx7455?An Investigational Room Temperature-Stable, Oral Microbiotabased Therapeutic Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)39863-4  0.315
2019 Blount K, Gerding DN, Khanna S, Pardi DS, Orenstein R, Dubberke ER, Jones CR, Mische S, Shannon B, Deych E. 624 – Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455—Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent Clostridium Difficile Infections Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)37115-X  0.336
2018 Vicens Q, Mondragón E, Reyes FE, Coish P, Aristoff P, Berman J, Kaur H, Kells KW, Wickens P, Wilson J, Gadwood RC, Schostarez HJ, Suto RK, Blount KF, Batey RT. Structure-activity relationship of flavin analogs that target the FMN riboswitch. Acs Chemical Biology. PMID 30107111 DOI: 10.2210/Pdb6Dn1/Pdb  0.396
2018 Vicens Q, Mondragón E, Reyes FE, Coish P, Aristoff P, Berman J, Kaur H, Kells KW, Wickens P, Wilson J, Gadwood RC, Schostarez HJ, Suto RK, Blount KF, Batey RT. Structure–Activity Relationship of Flavin Analogues That Target the Flavin Mononucleotide Riboswitch Acs Chemical Biology. 13: 2908-2919. DOI: 10.2210/Pdb6Dn1/Pdb  0.307
2018 Blount K, Jones C, Deych E, Shannon B. 1966. Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived From a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent Clostridium difficile Infections (rCDI) Open Forum Infectious Diseases. 5. DOI: 10.1093/Ofid/Ofy210.1622  0.34
2018 Wu Q, Ross C, Jones C, Blount K, Savidge T. 1775. Microbiome-Based Classifiers Accurately Differentiate Infectious Diarrhea From Functional Gastrointestinal Disorders and Provide Population-Scale Confidence Measures of Fecal Microbiota Restoration in Recurrent C. DifficileInfection Open Forum Infectious Diseases. 5: S67-S68. DOI: 10.1093/Ofid/Ofy209.160  0.308
2018 Khanna S, Pardi DS, Gerding DN, Blount K, Jones CR, Shannon B, Deych E. Tu1883 - A Lyophilized, Non-Frozen, Oral Microbiota-Based Drug RBX7455 is Safe, Reduces Clostridium Difficile Infection Recurrence, and Restores the Microbiome Gastroenterology. 154. DOI: 10.1016/S0016-5085(18)33509-1  0.352
2017 Khanna S, Blount K, Jones C, Shannon B, Carter S. Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile Open Forum Infectious Diseases. 4. DOI: 10.1093/Ofid/Ofx163.963  0.345
2017 Orenstein R, Dubberke ER, Khanna S, Hecht G, Dupont H, Lee C, Blount K, Carter S. RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent Clostridium difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results Open Forum Infectious Diseases. 4: S535-S535. DOI: 10.1093/Ofid/Ofx163.1393  0.302
2015 Blount KF, Megyola C, Plummer M, Osterman D, O'Connell T, Aristoff P, Quinn C, Chrusciel RA, Poel TJ, Schostarez HJ, Stewart CA, Walker DP, Wuts PG, Breaker RR. Novel Riboswitch-Binding Flavin Analog That Protects Mice against Clostridium difficile Infection without Inhibiting Cecal Flora. Antimicrobial Agents and Chemotherapy. 59: 5736-46. PMID 26169403 DOI: 10.1128/Aac.01282-15  0.347
2009 Kim JN, Blount KF, Puskarz I, Lim J, Link KH, Breaker RR. Design and antimicrobial action of purine analogues that bind Guanine riboswitches. Acs Chemical Biology. 4: 915-27. PMID 19739679 DOI: 10.1021/Cb900146K  0.347
2009 Lee ER, Blount KF, Breaker RR. Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. Rna Biology. 6: 187-94. PMID 19246992 DOI: 10.4161/Rna.6.2.7727  0.307
2007 Blount KF, Wang JX, Lim J, Sudarsan N, Breaker RR. Antibacterial lysine analogs that target lysine riboswitches. Nature Chemical Biology. 3: 44-9. PMID 17143270 DOI: 10.1038/Nchembio842  0.363
2006 Blount KF, Breaker RR. Riboswitches as antibacterial drug targets. Nature Biotechnology. 24: 1558-64. PMID 17160062 DOI: 10.1038/Nbt1268  0.348
2006 Blount K, Puskarz I, Penchovsky R, Breaker R. Development and application of a high-throughput assay for glmS riboswitch activators Rna Biology. 3: 77-81. PMID 17114942 DOI: 10.4161/Rna.3.2.3102  0.306
2006 Blount KF, Tor Y. A tale of two targets: differential RNA selectivity of nucleobase-aminoglycoside conjugates. Chembiochem : a European Journal of Chemical Biology. 7: 1612-21. PMID 16915600 DOI: 10.1002/Cbic.200600109  0.361
2005 Zhao F, Zhao Q, Blount KF, Han Q, Tor Y, Hermann T. Molecular recognition of RNA by neomycin and a restricted neomycin derivative. Angewandte Chemie (International Ed. in English). 44: 5329-34. PMID 16037995 DOI: 10.1002/Anie.200500903  0.375
2005 Blount KF, Zhao F, Hermann T, Tor Y. Conformational constraint as a means for understanding RNA-aminoglycoside specificity. Journal of the American Chemical Society. 127: 9818-29. PMID 15998086 DOI: 10.1021/Ja050918W  0.376
2005 Blount KF, Uhlenbeck OC. The structure-function dilemma of the hammerhead ribozyme. Annual Review of Biophysics and Biomolecular Structure. 34: 415-40. PMID 15869397 DOI: 10.1146/Annurev.Biophys.34.122004.184428  0.506
2003 Blount KF, Tor Y. Using pyrene-labeled HIV-1 TAR to measure RNA-small molecule binding. Nucleic Acids Research. 31: 5490-500. PMID 14500811 DOI: 10.1093/Nar/Gkg755  0.32
2002 Blount KF, Uhlenbeck OC. The hammerhead ribozyme. Biochemical Society Transactions. 30: 1119-22. PMID 12440986 DOI: 10.1042/Bst0301119  0.504
2002 Blount KF, Grover NL, Mokler V, Beigelman L, Uhlenbeck OC. Steric interference modification of the hammerhead ribozyme. Chemistry & Biology. 9: 1009-16. PMID 12323375 DOI: 10.1016/S1074-5521(02)00218-1  0.514
2002 Blount KF, Uhlenbeck OC. Internal equilibrium of the hammerhead ribozyme is altered by the length of certain covalent cross-links. Biochemistry. 41: 6834-41. PMID 12022888 DOI: 10.1021/Bi025596C  0.485
Show low-probability matches.